3:58 PM
 | 
Sep 21, 2012
 |  BC Extra  |  Company News

CHMP backs Eliquis, linaclotide

EMA's CHMP issued several positive opinions on Friday, including recommending approval to expand the indication of a 2.5 mg dose strength of Eliquis apixaban from Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) to include the prevention stroke and systemic embolism in adults with...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >